Syntis Bio: $38 Million Raised For Advancing Oral Therapies For Obesity
By Amit Chowdhry ● Yesterday at 9:05 AM
Syntis Bio, a clinical-stage biopharmaceutical company, has closed a $33 million Series A funding round led by Cerberus Ventures. New investors Mansueto Investments, Woori Venture Partners, and Apollo Labs joined the round, along with founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures, and Cerity Partners Ventures. The company also secured up to $5 million from NIH through SBIR awards.